INS and hyperlipidemia: The authors showed that short-term treatment (2 weeks) with an mTOR inhibitor causes hyperlipidemia and insulin resistance and promotes hepatic gluconeogenesis, whereas prolonged treatment (20 weeks) results in reduced adiposity, increased insulin sensitivity, improved lipid profile, and higher energy expenditure [46].